Aarti Drugs Limited (BOM: 524348)
539.85
-4.85 (-0.89%)
At close: Sep 10, 2024
Aarti Drugs Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | Mar '20 Mar 31, 2020 | 2019 - 2015 |
Operating Revenue | 24,228 | 25,286 | 27,161 | 24,886 | 21,548 | 18,061 | Upgrade
|
Other Revenue | - | - | - | 0 | - | - | Upgrade
|
Revenue | 24,228 | 25,286 | 27,161 | 24,886 | 21,548 | 18,061 | Upgrade
|
Revenue Growth (YoY) | -12.06% | -6.90% | 9.14% | 15.49% | 19.31% | 15.71% | Upgrade
|
Cost of Revenue | 15,912 | 16,970 | 19,102 | 17,022 | 13,319 | 11,876 | Upgrade
|
Gross Profit | 8,316 | 8,316 | 8,058 | 7,865 | 8,229 | 6,185 | Upgrade
|
Selling, General & Admin | 1,033 | 1,047 | 933.07 | 840.53 | 815.37 | 709.65 | Upgrade
|
Other Operating Expenses | 4,264 | 4,104 | 4,069 | 3,640 | 3,034 | 2,854 | Upgrade
|
Operating Expenses | 5,820 | 5,666 | 5,505 | 4,981 | 4,348 | 4,051 | Upgrade
|
Operating Income | 2,497 | 2,650 | 2,553 | 2,884 | 3,881 | 2,134 | Upgrade
|
Interest Expense | -336.9 | -335.15 | -332.93 | -207.48 | -229.57 | -337.26 | Upgrade
|
Interest & Investment Income | - | 24.97 | 7.02 | 23.16 | 36.2 | 11.28 | Upgrade
|
Other Non Operating Income (Expenses) | 0.04 | 15.33 | 14.92 | 0 | -0 | - | Upgrade
|
EBT Excluding Unusual Items | 2,160 | 2,355 | 2,242 | 2,700 | 3,688 | 1,808 | Upgrade
|
Asset Writedown | - | - | - | - | -30.42 | - | Upgrade
|
Other Unusual Items | - | - | - | - | 32.67 | 44.67 | Upgrade
|
Pretax Income | 2,160 | 2,355 | 2,242 | 2,700 | 3,690 | 1,853 | Upgrade
|
Income Tax Expense | 590.7 | 639.37 | 578.25 | 649.59 | 886.16 | 438.9 | Upgrade
|
Earnings From Continuing Operations | 1,569 | 1,716 | 1,664 | 2,050 | 2,804 | 1,414 | Upgrade
|
Net Income to Company | 1,569 | 1,716 | 1,664 | 2,050 | 2,804 | 1,414 | Upgrade
|
Minority Interest in Earnings | -0.84 | -1.73 | -0.48 | 0.43 | 0.15 | 0.02 | Upgrade
|
Net Income | 1,568 | 1,714 | 1,663 | 2,050 | 2,804 | 1,414 | Upgrade
|
Net Income to Common | 1,568 | 1,714 | 1,663 | 2,050 | 2,804 | 1,414 | Upgrade
|
Net Income Growth | -12.58% | 3.07% | -18.89% | -26.88% | 98.31% | 57.55% | Upgrade
|
Shares Outstanding (Basic) | 92 | 92 | 93 | 93 | 93 | 93 | Upgrade
|
Shares Outstanding (Diluted) | 92 | 92 | 93 | 93 | 93 | 93 | Upgrade
|
Shares Change (YoY) | -0.89% | -0.72% | - | -0.64% | - | -1.20% | Upgrade
|
EPS (Basic) | 17.09 | 18.65 | 17.96 | 22.14 | 30.09 | 15.17 | Upgrade
|
EPS (Diluted) | 17.01 | 18.65 | 17.96 | 22.14 | 30.09 | 15.17 | Upgrade
|
EPS Growth | -12.21% | 3.82% | -18.89% | -26.41% | 98.31% | 59.45% | Upgrade
|
Free Cash Flow | - | 1,326 | -314.97 | -815.61 | 667.19 | 2,028 | Upgrade
|
Free Cash Flow Per Share | - | 14.42 | -3.40 | -8.81 | 7.16 | 21.75 | Upgrade
|
Dividend Per Share | - | 1.000 | 1.000 | 1.000 | 2.500 | 0.500 | Upgrade
|
Dividend Growth | - | 0% | 0% | -60.00% | 400.00% | 100.00% | Upgrade
|
Gross Margin | 34.32% | 32.89% | 29.67% | 31.60% | 38.19% | 34.25% | Upgrade
|
Operating Margin | 10.30% | 10.48% | 9.40% | 11.59% | 18.01% | 11.82% | Upgrade
|
Profit Margin | 6.47% | 6.78% | 6.12% | 8.24% | 13.01% | 7.83% | Upgrade
|
Free Cash Flow Margin | - | 5.24% | -1.16% | -3.28% | 3.10% | 11.23% | Upgrade
|
EBITDA | 3,020 | 3,140 | 3,028 | 3,353 | 4,335 | 2,567 | Upgrade
|
EBITDA Margin | 12.47% | 12.42% | 11.15% | 13.47% | 20.12% | 14.21% | Upgrade
|
D&A For EBITDA | 523.94 | 489.77 | 475.43 | 469.4 | 453.3 | 432.82 | Upgrade
|
EBIT | 2,497 | 2,650 | 2,553 | 2,884 | 3,881 | 2,134 | Upgrade
|
EBIT Margin | 10.30% | 10.48% | 9.40% | 11.59% | 18.01% | 11.82% | Upgrade
|
Effective Tax Rate | 27.35% | 27.15% | 25.79% | 24.06% | 24.01% | 23.69% | Upgrade
|
Revenue as Reported | 24,274 | 25,326 | 27,182 | 25,000 | 21,593 | 18,076 | Upgrade
|
Advertising Expenses | - | 23.3 | 11.67 | 13.5 | 9.81 | 15.49 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.